retatrutide phase 2 trial weight loss 🚨Breaking: Retatrutide's first 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No plateau — curve still descending Retatrutide Safety, Side Effects &

Zepbound fits those targeting the highest mean losses who also have access through insurance programs that allow newer agents

Semaglutide has 31 amino-acid containing peptidic structure which is 94% homologous to the native GLP-1 for avoiding immunogenicity

Most people find that food noise returns to pre-treatment baseline over 4-8 weeks, even without intervention

In an interview with BioSpace , Rosanna Ricafort, vice president and head of late development hematology and cell therapy, said the field has come a long way in terms of toxicity management guidelines and an understanding of how to manage CAR T-associated toxicities that are well characterized. March 14 Product: BeiGenes Tevimbra Indication: Esophageal squamous cell carcinoma Also coming through on a jam-packed Thursday for the FDA was a nod for BeiGenes PD-1 blocker tislelizumabwhich will carry the brand name Tevimbrain unresectable or metastatic esophageal squamous cell carcinoma

Effectiveness and safety of GLP-1 agonist in obese patients with inflammatory bowel disease

Reducing systemic inflammation before it becomes disease